Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
UBS
US Department of Justice
Novartis
Moodys
McKinsey
Mallinckrodt
Harvard Business School
Argus Health
Express Scripts

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,977,329

« Back to Dashboard

Summary for Patent: 7,977,329
Title:5HT.sub.2C receptor modulators
Abstract: The present invention relates to novel compounds of Formula (I): ##STR00001## which act as 5HT.sub.2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Inventor(s): Smith; Jeffrey (San Diego, CA), Smith; Brian (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/599,050
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,977,329

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN ➤ Sign Up
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE ➤ Sign Up
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY ➤ Sign Up
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,977,329

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,953,787 5HT2C receptor modulators ➤ Sign Up
8,273,734 5HT.sub.2C receptor modulators ➤ Sign Up
8,546,379 5HT.sub.2C receptor modulators ➤ Sign Up
8,846,906 5HT.sub.2C receptor modulators ➤ Sign Up
8,993,750 5HT.sub.2C receptor modulators ➤ Sign Up
8,575,149 5HT2C receptor modulators ➤ Sign Up
7,514,422 5HT.sub.2c receptor modulators ➤ Sign Up
8,207,158 5HT2c receptor modulators ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,977,329

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 294781 ➤ Sign Up
Australia 2003221866 ➤ Sign Up
Brazil 0309303 ➤ Sign Up
Canada 2481723 ➤ Sign Up
China 100486967 ➤ Sign Up
China 101485664 ➤ Sign Up
China 101486677 ➤ Sign Up
China 101486678 ➤ Sign Up
China 101486679 ➤ Sign Up
China 1646493 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Dow
McKinsey
UBS
Merck
Chinese Patent Office
Argus Health
Express Scripts
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot